Ipsen Stock price

Equities

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris 12:35:52 2024-03-28 pm EDT 5-day change 1st Jan Change
110.3 EUR +1.01% Intraday chart for Ipsen +1.29% +2.22%
Sales 2024 * 3.46B 3.73B Sales 2025 * 3.7B 3.99B Capitalization 9.11B 9.81B
Net income 2024 * 647M 697M Net income 2025 * 725M 781M EV / Sales 2024 * 2.46 x
Net cash position 2024 * 608M 655M Net cash position 2025 * 1.24B 1.33B EV / Sales 2025 * 2.13 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
12.6 x
Employees 5,325
Yield 2024 *
1.07%
Yield 2025 *
1.09%
Free-Float 41.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.01%
1 week+1.29%
Current month+8.35%
1 month+8.56%
3 months+2.41%
6 months-10.03%
Current year+2.22%
More quotes
1 week
107.60
Extreme 107.6
111.50
1 month
99.70
Extreme 99.7
111.50
Current year
99.70
Extreme 99.7
111.50
1 year
99.70
Extreme 99.7
130.70
3 years
69.50
Extreme 69.5
130.70
5 years
34.20
Extreme 34.2
130.70
10 years
28.24
Extreme 28.235
155.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 20-06-30
Director of Finance/CFO 54 14-11-02
Chairman 66 10-11-21
Members of the board TitleAgeSince
Director/Board Member 66 17-06-06
Director/Board Member 61 22-01-20
Director/Board Member 65 15-05-26
More insiders
Date Price Change Volume
24-03-28 110.3 +1.01% 106,351
24-03-27 109.2 +0.83% 51,965
24-03-26 108.3 -1.10% 69,726
24-03-25 109.5 +0.37% 61,465
24-03-22 109.1 +0.18% 119,187

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
110.3 EUR
Average target price
123 EUR
Spread / Average Target
+11.51%
Consensus
  1. Stock
  2. Equities
  3. Stock Ipsen - Euronext Paris